Comments
Loading...

Ultragenyx Pharmaceutical

RARENASDAQ
Logo brought to you by Benzinga Data
$57.70
-0.79-1.35%
At Close: -
$57.70
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Consensus Rating1
Buy
Highest Price Target1
$133.00
Lowest Price Target1
$46.00
Consensus Price Target1
$91.72

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock, Analyst Ratings, Price Targets, Forecasts

Ultragenyx Pharmaceutical Inc has a consensus price target of $91.72 based on the ratings of 25 analysts. The high is $133 issued by Citigroup on June 7, 2023. The low is $46 issued by Wedbush on August 2, 2024. The 3 most-recent analyst ratings were released by Cantor Fitzgerald, Barclays, and Wells Fargo on September 16, 2024, August 5, 2024, and August 2, 2024, respectively. With an average price target of $90.67 between Cantor Fitzgerald, Barclays, and Wells Fargo, there's an implied 57.13% upside for Ultragenyx Pharmaceutical Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Jun
1
1
Jul
3
1
Aug
1
Sep
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.2
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Cantor Fitzgerald
Barclays
Wells Fargo
Goldman Sachs
Wedbush

1calculated from analyst ratings

Analyst Ratings for Ultragenyx Pharmaceutical

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Ultragenyx Pharmaceutical (RARE) stock?

A

The latest price target for Ultragenyx Pharmaceutical (NASDAQ:RARE) was reported by Cantor Fitzgerald on September 16, 2024. The analyst firm set a price target for $116.00 expecting RARE to rise to within 12 months (a possible 101.04% upside). 38 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Ultragenyx Pharmaceutical (RARE)?

A

The latest analyst rating for Ultragenyx Pharmaceutical (NASDAQ:RARE) was provided by Cantor Fitzgerald, and Ultragenyx Pharmaceutical reiterated their overweight rating.

Q

When was the last upgrade for Ultragenyx Pharmaceutical (RARE)?

A

The last upgrade for Ultragenyx Pharmaceutical Inc happened on June 6, 2024 when Goldman Sachs raised their price target to $67. Goldman Sachs previously had a neutral for Ultragenyx Pharmaceutical Inc.

Q

When was the last downgrade for Ultragenyx Pharmaceutical (RARE)?

A

The last downgrade for Ultragenyx Pharmaceutical Inc happened on August 1, 2022 when Evercore ISI Group changed their price target from $95 to $60 for Ultragenyx Pharmaceutical Inc.

Q

When is the next analyst rating going to be posted or updated for Ultragenyx Pharmaceutical (RARE)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ultragenyx Pharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ultragenyx Pharmaceutical was filed on September 16, 2024 so you should expect the next rating to be made available sometime around September 16, 2025.

Q

Is the Analyst Rating Ultragenyx Pharmaceutical (RARE) correct?

A

While ratings are subjective and will change, the latest Ultragenyx Pharmaceutical (RARE) rating was a reiterated with a price target of $116.00 to $116.00. The current price Ultragenyx Pharmaceutical (RARE) is trading at is $57.70, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch